List of Bunavail drug patents
Bunavail is owned by Bdsi.
Bunavail contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.
Bunavail has a total of 4 drug patents out of which 0 drug patents have expired.
Bunavail was authorised for market use on 06 June, 2014.
Bunavail is available in film;buccal dosage forms.
Bunavail can be used as treatment of opioid dependence, maintenance treatment of opioid dependence.
The generics of Bunavail are possible to be released after 24 April, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
| US8703177 | BDSI | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
Aug, 2032
(9 years from now) | |
| US9522188 | BDSI | Abuse resistant transmucosal drug delivery device |
Apr, 2035
(12 years from now) | |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence
Dosage: FILM;BUCCAL
BUNAVAIL family patents
40
United States
8
Japan
6
Australia
5
China
5
European Union
4
Brazil
4
Canada
3
Russia
3
New Zealand
3
Norway
3
Korea, Republic of
3
Hong Kong
3
Israel
2
Singapore
2
Spain
2
Mexico
2
EA
1
Croatia
1
South Africa
1
Cyprus
1
Slovenia
1
Hungary
1
Ukraine
1
Poland
1
RS
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic